The American Cancer Society updated colorectal cancer screening guidelines to include additional blood- and stool-based options, while refining how clinicians should choose among tests. The new recommendations, published in CA: A Cancer Journal for Clinicians, add Shield (Guardant), SimpleScreen (Freenome), ColoSense (Geneoscopy), and Cologuard Plus (Abbott). Notably, the guideline expansion aligns with the expanding menu of non-invasive screening tests that aim to improve access through at-home or blood-based workflows. For health systems, the update can affect test ordering patterns and payer coverage decisions, particularly where participation gaps remain. The guidance also reflects growing emphasis on flexibility in screening strategy—supporting clinicians in matching test choice to patient preferences and risk profiles while ensuring quality of screening performance in routine practice.